Migratory and Angiogenic Dysfunction of Circulating CD133 Stem Cells: a New Prognostic Marker in Myocardial Ischemia.
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 170
- 试验地点
- 2
- 主要终点
- Prognostic value of CD133+ stem cells in MI
研究概览
简要总结
The present project aims to determine whether a deficit in migration of stem cells could be implicated in the failure to mount an adequate collateralization after Myocardial Infarction (MI) and thereby facilitate the development of post-ischemic heart failure (HF) and to dissect underlying molecular mechanisms. Furthermore, the investigators wish to determine the predictive value of stem cell migration assay in patients with MI.
详细描述
MAIN OBJECTIVES OF THE STUDY:
Characterization of circulating CD133+ stem cells in a group of 170 patients with MI (mean post-MI follow up, 6 months):
- Counting total mononuclear cells and FACS analysis of CD133 stem cells.
- Characterization of CD133+ stem cell biology: Migratory assay, imaging of cytoskeleton, angiogenesis tests in vitro.
- Evaluation of migratory signalling, with specific focus on the PI3K/Akt/eNOS system.
Assessment of the prognostic value of the stem cell migration assay.
- Relationship between cell biology tests on CD133+ cells and changes in circulating cytokines and pro-angiogenic factors after MI.
- Assessment of area at risk by ECG-synchronized Single Photon Emission Computed Tomography (gated-SPECT) in subgroups with different patterns of stem cell migratory tests.
- Assessment of ventricular remodelling (echocardiography, NMR) in relation with patterns of stem cell migratory test.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age >= 18 years
- •Thoracic pain lasting at least 20 min and ST changes or left B block, not present in previous ECG.
- •MI confirmed by elevation of troponin I and CK-MB.
- •Patients with Killip II e III LV dysfunction will be included.
排除标准
- •Patients reporting thoracic pain 24 hours prior to hospitalization
- •HF symptoms resistant to therapy
- •Haemoglobin< 10 gr/dl
- •Haemodynamic instability (systolic pressure <90 mmHg after treatment)
- •Alterations in haematopoiesys
- •Concurrent neoplastic disease
- •No written informed consent or other conditions that affect patient's compliance to protocol.
结局指标
主要结局
Prognostic value of CD133+ stem cells in MI
时间窗: 12 months
Correlation of clinical parameters of disease evolution and biological features
次要结局
- Correlation of disease evolution and other biomarkers(12 months)